Aachen Resonance GmbH

Pauwelsstrasse 19, 52074 Aachen, Tel. +49-(0)241-97900905, Fax +49-

(0)241-97900907, E-Mail: info@aachenresonance.de

Press Release
Aachen, Germany, 14.01.2009

Aachen Resonance announces for 2009 the distribution of the ELUTAX, Drug
eluting Balloon, through Biotronik sales in Switzerland, Belgium, Netherland,
Luxemburg, England, Ireland and Italy.
BIOTRONIK is especially present in these markets offering products for
diagnosis, treatment and in the areas of cardiac rhythm management,
electrophysiology, and vascular intervention.

The main application of Drug eluting Balloons is restenosis of vascular lesions

after angioplasty or stent placement, restenosis occurs in 5 to 30% of
treatments. The restenosis is caused by neointimal cell hyperplasia. Local
administration of lipophilic taxane compounds can inhibit the proliferation of
such cells for a long period.

The Aachen Resonance Elutax Drug eluting Balloon is developed especially

for coronary arteries and venous by-pass as well as for small vessels in
peripheral and supraaortic regions. The balloon is coated with 2
microgram/mm2 of pure Paclitaxel.
The drug surface contains two layers. The Base coating to ensure the Drug
attachment (consistency of ICE) and the Top coating (consistency of
SNOW). No polymer, nor any other agent are used to ensure the Drug
attachment.
The SNOW Layer is responsible for the Drug uptake as it releases the Drug in
appropriate conditions for an effective penetration into the vessel wall.

About Aachen Resonance:

Aachen Resonance is a leading European manufacturer of medical

technology with a worldwide market presence. The company offers a
complete line of products for treatment and advanced therapy support in
vascular intervention, working in close cooperation with the University of
Technology in Aachen.

Its main focus is developing new devices with improved biocompatibility

The field of vascular intervention consists of balloon catheters, stents, drug

eluting stents and drug eluting balloons for coronary and peripheral
applications.

The company invests heavily in research and development, and is pursuing

important, future-oriented approaches to cardiovascular therapy. Currently,
Aachen Resonance maintains three headquarters in Europe for research,
development and manufacturing.

Aachen Resonance is market leader in Europe for Drug eluting balloons.

Contact address:

Dr. Alexander Ruebben, CEO

Aachen Resonance GmbH

Pauwelsstrasse 19
D-52074 Aachen
Germany

Tel. 0049 241 97900905

Fax. 0049 241 97900907
www.aachen-resonance.com
Email: ruebben@gmx.net